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Abstract
Background: Promoting the neuroprotective and repair-inducing effector functions of microglia and macrophages,
by means of M2 polarisation or alternative activation, is expected to become a new therapeutic approach for
central nervous system (CNS) disorders in which detrimental pro-inflammatory microglia and/or macrophages
display a major contribution to the neuropathology. In this study, we present a novel in vivo approach using
intracerebral grafting of mesenchymal stem cells (MSC) genetically engineered to secrete interleukin 13 (IL13-MSC).
Methods: In the first experimental setup, control MSC and IL13-MSC were grafted in the CNS of eGFP+ bone
marrow chimaeric C57BL/6 mice to histologically evaluate IL13-mediated expression of several markers associated
with alternative activation, including arginase1 and Ym1, on MSC graft-recognising microglia and MSC graft-
infiltrating macrophages. In the second experimental setup, IL13-MSC were grafted on the right side (or on both
the right and left sides) of the splenium of the corpus callosum in wild-type C57BL/6 mice and in C57BL/6
CX3CR1
eGFP/+CCR2RFP/+ transgenic mice. Next, CNS inflammation and demyelination was induced by means of a
cuprizone-supplemented diet. The influence of IL13-MSC grafting on neuropathological alterations was monitored
by non-invasive T2-weighted magnetic resonance imaging (MRI) and quantitative histological analyses, as compared
to cuprizone-treated mice with control MSC grafts and/or cuprizone-treated mice without MSC injection.
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Results: In the first part of this study, we demonstrate that MSC graft-associated microglia and MSC graft-infiltrating
macrophages are forced into alternative activation upon grafting of IL13-MSC, but not upon grafting of control
MSC. In the second part of this study, we demonstrate that grafting of IL13-MSC, in addition to the recruitment of
M2 polarised macrophages, limits cuprizone-induced microgliosis, oligodendrocyte death and demyelination.
Furthermore, we here demonstrate that injection of IL13-MSC at both sides of the splenium leads to a superior
protective effect as compared to a single injection at one side of the splenium.
Conclusions: Controlled and localised production of IL13 by means of intracerebral MSC grafting has the potential
to modulate cell graft- and pathology-associated microglial/macrophage responses, and to interfere with
oligodendrocyte death and demyelinating events in the cuprizone mouse model.
Keywords: Interleukin 13, Mesenchymal stem cells, Neuroinflammation, Transplantation, Magnetic resonance
imaging
Background
Detrimental inflammatory responses in the central nervous
system (CNS) are a hallmark of various neurodegenerative
pathologies, with multiple sclerosis (MS), stroke and trau-
matic brain or spinal cord injury being excellent examples
of the complex interplay between CNS-resident microglia
and lesion-infiltrating leukocytes [1–4]. Although microglia
and CNS-invading peripheral monocytes both act as
phagocytic cells of the brain, it is currently becoming ac-
cepted that these two cell types are more distinct than gen-
erally assumed [2, 5]. This is supported by observations in
various models of neuroinflammation in which microglia
and bone marrow (BM)-derived macrophages may be
present at different time points, may have a different spatial
distribution and, more importantly, may display different
functions and/or phenotypes during the course of neu-
roinflammation and neurodegeneration [5]. Neverthe-
less, in the early stage of neuroinflammatory responses,
lesion-associated microglia and/or macrophages are gener-
ally described as ‘classically or M1 activated’, i.e. displaying
a phenotype and function comparable to in vitro LPS- and/
or IFNγ-activated macrophages [6]. M1 activated macro-
phages are thus highly pro-inflammatory and cytotoxic,
with their main effector functions being the destruction
and removal of damaged or infected cells. From an emer-
ging therapeutic point of view, it is suggested that forced
‘alternative or M2 activation’ of lesion-associated microglia
and/or macrophages during the development of inflamma-
tory responses can have a beneficial effect on disease out-
come [5]. M2-activated macrophages are thus suggested to
be anti-inflammatory, with their main effector functions
being protection and regeneration of injured or diseased
tissue. Although dependent on the stimuli applied, several
directions of alternative macrophage activation can be
achieved in vitro and in vivo [6]. In this study, we aimed to
investigate the potential of interleukin 13 (IL13) [7]
to modulate microglia and/or macrophage activation in
vivo in an attempt to influence pathology-associated
neuroinflammation.
One of the major challenges in current CNS immuno-
modulation research is how to effectively deliver thera-
peutic proteins (in casu IL13) directly to the site of
neuroinflammation. While several methods of delivery can
be implemented [8], including (i) direct protein injection,
(ii) non-viral and viral gene therapy and (iii) implantation
of genetically engineered cellular grafts, each of them has
specific advantages and disadvantages. Whereas direct pro-
tein injection would be the most straightforward, it would
require multiple injections as, in the case of IL13, sustained
therapeutic protein expression may be essential. Alterna-
tively, mechanical or chemical methods (e.g. electropor-
ation, ultrasound or lipoplexes) may be applied to transfer
plasmid DNA encoding the therapeutic protein of interest
into inflammatory cells at the site of neuroinflammation.
Nevertheless, these techniques are still poorly efficient and
need further optimisation for in vivo application. On the
other hand, gene transfer in the CNS by means of viral
vectors is highly efficient in rodents but remains controver-
sial in terms of clinical translation to humans, despite
many efforts undertaken to control gene insertion, protein
expression and/or unwanted immune reactions. Lastly,
transplantation of genetically engineered (stem) cell popu-
lations is an emerging methodological approach for in situ
delivery of therapeutic proteins [9, 10]. Preceding work by
our group has already extensively compared the in vivo be-
haviour of neural stem cell (NSC) and mesenchymal stem/
stromal cell (MSC) grafts upon implantation in the CNS of
mice [11–16]. Based on our published reports, we have a
strong preference for MSC as a cellular carrier to deliver
therapeutic proteins due to their relatively easy ex vivo cul-
ture, susceptibility for genetic modification and their more
robust survival upon grafting in CNS tissue com-
pared to NSC. In this study, we aim to investigate
whether in situ grafting of MSC genetically engineered to
express IL13 can influence neuroinflammatory responses,
both on the level of cell graft-associated inflammatory
responses and on the level of pathology-associated inflam-
matory responses.
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In order to address these questions, we investigated the
behaviour of control MSC and IL13-expressing MSC grafts
both under healthy and under inflammatory CNS condi-
tions. For the latter, we used the well-established cuprizone
(CPZ) mouse model of CNS inflammation, oligodendro-
cyte death and subsequent demyelination [17]. Further-
more, in order to separately investigate the behaviour of
brain-resident microglia and CNS-invading peripheral
macrophages, part of the experiments presented in this
study were performed in the CX3CR1
eGFP/+ CCR2RFP/+




Wild-type C57BL/6 mice were obtained via Charles River
Laboratories (strain code 027). Transgenic C57BL/6-eGFP
mice (strain code 003291), CX3CR1
eGFP/eGFP mice (strain
code 005582) and CCR2RFP/RFP mice (strain code 017586)
were obtained via Jackson Laboratories. CX3CR1
eGFP/+
CCR2RFP/+ mice were obtained by breeding CX3CR1
eGFP/
eGFP mice with CCR2RFP/RFP mice. During the entire study,
the mice were kept in the animalarium of the University
of Antwerp (UA) under normal day-night cycle (12/12)
with free access to food and water. All animal experimen-
tal procedures were approved by the Ethics Committee
for Animal Experiments of the UA (approval no. 2011–13
and 2012–39).
Lentiviral vector production
The pCHMWS-IL13-IRES-Pac lentiviral vector (LVv) plas-
mid was constructed by replacing the eGFP cDNA insert
(SpeI/XbaI digest) from the pCHMWS-eGFP-IRES-Pac
plasmid (provided by the Leuven viral vector core, Molmed,
KULeuven, Belgium) with the IL13 cDNA (NcoI/NheI di-
gest) from the pORF-mIL13 plasmid (InvivoGen) using
standard subcloning techniques. Before proceeding to LVv
production, the pCHMWS-IL13-IRES-Pac plasmid was
electroporated in K562 cells followed by stable selection by
addition of puromycin to the culture medium. Expression
of IL13 was confirmed by a murine IL13 ELISA (Peprotech)
using the supernatant of stably transfected puromycin-
resistant K562 cells. Following confirmation of IL13 expres-
sion and Pac functionality, LVv production was outsourced
to the Leuven viral vector core [18, 19].
Culture and genetic engineering of MSC
In this study, we used a previously established and charac-
terised C57BL/6 mouse BM-derived MSC line (further
named as parental MSC) [20] and a derivative thereof, gen-
etically engineered to express the blue fluorescent protein
(further named as blue fluorescent protein (BFP)-MSC)
[13]. For expansion, both MSC lines were cultured in
standard cell culture plasticware (well plates and/or culture
flasks) in ‘complete expansion medium’ (CEM) [21] con-
sisting of Iscove’s modified Dulbecco’s medium (IMDM;
Lonza) supplemented with 8% fetal bovine serum (FBS;
Invitrogen), 8% horse serum (HS; Invitrogen), 200U/ml +
100 μg/ml penicillin/streptomycin (Invitrogen) and 1 μg/
ml amphotericin B (Invitrogen). Culture medium for BFP-
MSC was further supplemented with 1 μg/ml puromycin
(InvivoGen). MSC cultures were split 1:5 twice a week
using 0.05% trypsin-EDTA (Invitrogen) for cell detach-
ment. Both the parental MSC line and the BFP-MSC line
were transduced with the pCHMWS-IL13-IRES-Pac LVv,
according to previously optimised procedures [13, 21]. Fol-
lowing puromycin selection, the resulting engineered MSC
lines were further named as IL13-MSC and IL13/BFP-
MSC. Culture medium for both IL13-MSC and IL13/BFP-
MSC was further supplemented with 5 μg/ml puromycin.
Expression of IL13 was confirmed by a murine IL13
ELISA, demonstrating a secretion of 184 ± 44 ng IL13/6 ×
104 cells/24 h by IL13-MSC and 76 ± 3 ng IL13/6 × 104
cells/24 h by IL13/BFP-MSC. No IL13 secretion was de-
tected in BFP-MSC cultures. IL13-MSC were used in three
experiments, and IL13/BFP-MSC were used in one experi-
ment out of four in the cuprizone mouse model. To avoid
confusion, both IL13-producing cell lines will be referred
to as IL13-MSC further in text.
Bone marrow transplantation experiments
In order to discriminate between microglia and macro-
phages, eGFP+ BM chimaeric mice were generated as pre-
viously described [13]. Briefly, wild-type C57BL/6 mice
received 10Gy total body irradiation using an XRAD320
small animal irradiation device (Precision X-Ray). For this,
groups of five non-anesthetised mice were placed in a sin-
gle cage within the whole irradiation field (without head
protection). Six hours post-irradiation, a single intravenous
injection of total eGFP+ BM cells (1.5 × 106 cells in 100 μl
phosphate buffered saline) was administered via the
tail vein. Total BM cells were isolated from 8-week-
old C57BL/6-eGFP mice by flushing dissected femurs and
tibias with sterile phosphate buffered saline (PBS). Before
administration, total BM cells were filtered over a 70-μm
sterile mesh (Becton Dickinson), centrifuged and suspended
in PBS. During recovery, mice were treated with enrofloxa-
cin (1 μl/ml; Baytril 10%; Bayer) added to the drinking
water for 8 weeks post-irradiation.
Cell implantation experiments
All surgical experiments were performed under sterile con-
ditions, as previously described [22–24]. Briefly, mice were
anesthetised by an intraperitoneal injection of a ketamine
(80 mg/kg, Pfizer) + xylazine (16 mg/kg, Bayer Health Care)
mixture in PBS and placed in a stereotactic frame (Stoelt-
ing). A midline scalp incision was made and a hole was
drilled in the skull using a dental burr drill (Stoelting) at the
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following coordinates relative to bregma: (i) 2.3 mm dextra
for injections in healthy mice, or (ii) 0.3 mm dextra at
1.6 mm posterior for injections in CPZ-treated mice or (iii)
0.3 mm dextra and 0.3 mm sinistra at 1.6 mm posterior for
double injections in CPZ-treated mice. Next, an automatic
microinjector pump (kdScientific) with a 10 μl Hamilton
syringe was positioned above the exposed dura. A 30-gauge
needle (Hamilton), attached to the syringe, was placed
through the intact dura to a depth of 2.3 mm for injections
in healthy mice (directly underneath the capsula externa)
and to a depth of 1.3 mm in CPZ-treated mice (directly
within the right side or both left and right sides of the sple-
nium of the corpus callosum). After 2 min of pressure
equilibration, a suspension of 2 × 104 MSCs in a volume of
0.4 μl was injected in CPZ-treated mice or a suspension of
2 × 105 MSCs in a volume of 2 μl was injected in healthy
mice. The needle was retracted after another 4 min to allow
pressure equilibration and to prevent backflow of the
injected cell suspension. Next, the skin was sutured (Vicryl,
Ethicon) and 100 μl of a 0.9% NaCl solution (Baxter) was
administered subcutaneously in order to prevent de-
hydration while mice were placed under a heating
lamp to recover.
Cuprizone mouse model
For induction of CNS inflammation and demyelination,
mice received standard rodent chow mixed with 0.2 %
w/w CPZ (Sigma-Aldrich) for 4 weeks between the ages
of 8 and 12 weeks, as previously described [14, 25–27].
Magnetic resonance imaging acquisition
For the first study setup, in which a single injection on the
right side of the splenium was performed in CPZ-treated
mice, in vivo imaging experiments were conducted at
400 MHz on a 9.4T Bruker Biospec system (Biospec 94/20
USR, Bruker Biospin) using a standard Bruker cross coil
setup, with a quadrature volume coil for excitation and a
quadrature mouse surface coil for signal detection. For the
second study setup, in which a double injection on both
the right side and the left side of the splenium was per-
formed in CPZ-treated mice, in vivo imaging experiments
were conducted at 400 MHz on a 7T Pharmascan MR
scanner (Bruker, Germany). This system is equipped with a
standard Bruker cross coil setup, with a quadrature volume
coil for excitation and an array mouse surface coil for signal
detection. During imaging, mice were anesthetised using
2% isoflurane (Isoflo®, Abbot Laboratories Ltd.) in a mix-
ture of 30% O2 and 70% N2O at a flow rate of 600 ml/min.
Mice were fixed in an animal restrainer with ear bars and a
tooth bar. Respiratory rate was continuously monitored,
and body temperature was measured and maintained con-
stant at 37 °C using a feedback coupled warm air system
(MR compatible Small Animal Monitoring and Gating Sys-
tem, SA instruments, Inc.). T2 values were acquired with
the multi-slice multi-echo (MSME) sequence that is based
on the Carr-Purcell-Meiboom-Gill (CPMG) sequence,
where transverse magnetization of a 90° pulse is refocused
by a train of 180° pulses generating a series of echoes. For
the study setup with a single injection on the right side of
the splenium, the following imaging parameters were used:
number of averages (NA) = 1; number of slices (NS) = 6
with a slice thickness of 0.4 mm and an interslice thickness
of 0.4 mm; number of echoes = 10 with echo spacing =
8.5 ms (echo times (TE) being 8.5; 17; 25.5; 34; 42.5; 51;
59.5; 68; 76.5; 85); a repetition time (TR) = 4000 ms; field of
view (FOV) = 2.0 × 2.0 cm; matrix size = 256 × 256 (this
yields an effective in-plane resolution of 0.078 × 0.078 mm).
The total acquisition time per analysis was 12 min 48 s. For
the study setup with double injection on both the right and
left sides of the splenium, the following parameters were
used: NA = 1; NS = 6 with a slice thickness of 0.4 mm and
an interslice thickness of 0.4 mm; number of echoes = 10
with echo spacing = 8.7 ms (TE being 8.7; 17;4; 26.1; 34.8;
43.5; 52; 60.9; 69.6; 78.3; 87); TR = 4000 ms; FOV = 2.5 ×
2.5 cm; matrix size = 256 × 256 (this yields an effective in-
plane resolution of 0.098 × 0.098 mm). The total acquisition
time per analysis was 12 min 48 s.
Magnetic resonance imaging processing
T2 maps were generated with custom-built programmes
written in MATLAB (MATLAB R2011b, The MathWorks
Inc.) using a monoexponential fit function [y =A +C*exp
(−t/T2)], where A = absolute bias, C = signal intensity and
T2 = transverse relaxation time. Regions of interest (ROIs)
were drawn manually on the T2-weighted images, accord-
ing to a mouse brain atlas, with AMIRA software (Mer-
cury Computer systems) and regional average T2 values
were calculated. ROIs included the external capsule (EC)
and the splenium of the corpus callosum (CC), which was
further divided in two parts in respect to the brain’s mid-
line and later referred as the right and the left sides of the
splenium.
Immunofluorescence analysis
All immunofluorescence analyses were performed ac-
cording to previously described procedures [22, 23].
Mice were transcardially perfused with 0.9 % NaCl solu-
tion followed by 4% paraformaldehyde (PFA) solution.
Next, brains were isolated and further fixed in 4 % PFA
for 3 h, then dehydrated through a sucrose gradient of 5,
10 and 20 %. Afterwards, brain tissue was snap-frozen in
liquid nitrogen and kept at −80 °C until further process-
ing. Ten-micrometer-thick cryosections were made using
a microm HM500 cryostat. Immunofluorescence staining
was performed on brain slides using the following antibody
combinations: a primary goat anti-MBP antibody (1 μg/ml,
Santa Cruz, sc-13914) with a secondary donkey anti-goat
Alexa Fluor 350 antibody (20 μg/ml, Invitrogen,A21081); a
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primary rabbit anti-Iba1 antibody (1 μg/ml, Wako, 019-
19741) with a secondary donkey anti-rabbit Alexa Fluor 555
(2 μg/ml, Invitrogen, A31572); a primary rabbit anti-GFAP
antibody (4.5 μg/ml, Abcam, ab7779) with a secondary don-
key anti-rabbit Alexa Fluor 555 antibody; a primary rat anti-
F4/80 antibody (4 μg/ml, AbD serotec, MCA497GA) with a
secondary goat anti-rat Cy5 antibody (10 μg/ml, Invitrogen,
A10525); a primary rat anti-MHCII antibody (2.5 μg/ml,
eBioscience, 14-5321-82) with a secondary goat anti-rat
Alexa Fluor 555 or goat anti-rat Alexa Fluor 350 antibody
(10 μg/ml, Invitrogen, A21093); a primary goat anti-Arg1
antibody (2 μg/ml, Santa Cruz, sc-18354) with a sec-
ondary donkey anti-goat Alexa Fluor 555 (10 μg/ml,
Invitrogen, A21432) or donkey anti-goat Cy5 antibody
(10 μg/ml, Abcam, AB6566); a primary rabbit anti-Ym1
antibody (0.4 μg/ml, Stemcell Technologies, 01404) with a
secondary donkey anti-rabbit Alexa Fluor 555 antibody; a
primary chicken anti-MBP antibody (0.5 μg/ml, Millipore,
AB9348) with a secondary donkey anti-chicken Cy3 anti-
body (7.5 μg/ml, Jackson Immunoresearch, JIR703-166-
155); and a primary mouse anti-CC1 antibody (0.5 μg/ml,
Millipore, OP80) with a secondary goat anti-mouse Alexa
Fluor 555 antibody (10 μg/ml, Invitrogen, A21425).
Histological quantification
Quantitative phenotypic analyses of microglia and macro-
phage and responses following MSC grafting in bone mar-
row chimaeric mice were performed using TissueQuest
immunofluorescence analysis software (TissueGnostics
GmbH, v3.0), as previously described by our group [12,
13, 15, 23]. Briefly, for each of the slides analysed, the
MSC graft site was manually delineated based on nuclear
TOPRO-3 staining. The MSC graft site border was then
determined as a region extending 85 μm from the MSC
graft site. According to previously established procedures,
the following parameters were determined: the cellular
density of (i) eGFP+ macrophages (three slides per cell graft
analysed), (ii) MHCII+ eGFP+ macrophages (one slide per
cell graft analysed), (iii) Arg1+ eGFP+ macrophages (one
slide per cell graft analysed), (iv) Iba1+ cells (one slide per
graft analysed) and (v) MHCII+ Arg1+ cells (one slide per
cell graft analysed). Quantitative analyses of microglial in-
flammation and/or demyelination in the cuprizone mouse
model were performed using NIH ImageJ analysis software
(v1.47), according to previously established procedures [13,
15, 23]. Briefly, the following parameters were determined
for the whole splenium and the right and the left sides of
the splenium: (i) percentage of eGFP coverage (three slides
per mouse brain analysed) and (ii) percentage of MBP
coverage (one to three slides per mouse brain analysed). In
addition, the cellular density of CC1+ oligodendrocytes
was determined using TissueQuest software (one slide
per mouse brain analysed).
Statistical analyses
For the results obtained following MSC implantation in
the CNS of healthy eGFP+ bone marrow chimaeric mice,
the following statistical analyses were applied. (i) Differ-
ences in cellular density of MHCII- and Arg1-expressing
eGFP− microglia and eGFP+ macrophages within the im-
plant site and the implant border of BFP-MSC and IL13-
MSC grafts were analysed using Wilcoxon tests. (ii)
Differences in cellular density of all subgroups present in
the implant site and the implant border of BFP-MSC and
IL13-MSC grafts, based on eGFP, MHCII and Arg1 ex-
pression were analysed using Wilcoxon tests. However,
because groups were very small (n = 5 or 6), the p value
produced by this test is bounded by a non-significant min-
imal value. We therefore used t tests when normality was
not rejected. We here rely on the normality assumption,
since normality tests suffer from low power in this low
sample size setting. p values were corrected for multiple
testing using the false discovery rate method [28]. For the
results obtained following MSC grafting in the cuprizone
mouse model, the following statistical analyses were ap-
plied. (i) Comparisons of mean T2-relaxation times of the
left, right and whole splenium of the CC, and the EC be-
tween healthy mice, CPZ-treated mice, BFP-MSC grafted
CPZ-treated mice and IL13-MSC grafted CPZ-treated
mice (right side injection) were analysed using a two-way
ANOVA, with the obtained p values being corrected for
multiple testing using the Tukey HSD post hoc test. In
this way, possible differences between the three experi-
ments are taken into account. (ii) Comparisons of mean
T2 relaxation times of the left, right and whole splenium,
and the EC between healthy mice, CPZ-treated mice and
IL13-MSC injected mice (right and left side injection)
were analysed using non-parametric Wilcoxon tests, with
the given p values being corrected for multiple testing
using the false discovery rate method. (iii) Comparisons of
the percentages of eGFP and MBP coverage in the left,
right and whole splenium of CX3CR1
eGFP/+ CCR2RFP/+
mice between healthy mice, CPZ-treated mice, BFP-MSC
grafted CPZ-treated mice and IL13-MSC grafted CPZ-
treated mice (right side injection) were analysed by using
GEE, with the given p values being corrected for multiple
testing using the false discovery rate method [29]. (iv)
Comparisons of MBP coverage percentages and CC1+ cell
density in the left, right and whole splenium between
healthy mice, CPZ-treated mice and IL13-MSC injected
mice (right and left side injection) were analysed using a
Wilcoxon rank sum test, with the given p values being
corrected for multiple testing using the false discovery rate
method. (v) The dependence between eGFP and MBP
coverage percentage (right side injection), eGFP coverage
percentage and T2 relaxation times (right side injection),
MBP coverage percentage and T2 relaxation times (right
side injection), MBP coverage percentage and CC1+ cell
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density (right and left side injection), MBP coverage per-
centage and T2 relaxation times (right and left side injec-
tion) and CC1+ cell density and T2 relaxation times (right
and left side injection) was measured using the Spearman
correlation coefficient. A bootstrap procedure was used to
construct 95 % confidence intervals. Correlation coefficients
and confidence intervals are stated in the results section.
Results
Transplantation of IL13 producing MSC in the CNS locally
induces expression of markers associated with alternative
activation in microglia and macrophages
In the first part of this study, we investigated whether
microglia, macrophage or astrocyte behaviour was altered
upon implantation of IL13-producing MSC (n = 5) as com-
pared to implantation of control blue fluorescent protein
(BFP)-expressing MSC (n = 6) in the CNS of healthy mice.
In order to discriminate between microglia and macro-
phages, BFP-MSC and IL13-MSC were grafted in eGFP+
bone marrow chimaeric mice, and MSC grafts were histo-
logically analysed at day 10 post-grafting. As shown by the
representative immunofluorescence images in Fig. 1a, a
GFAP+ astroglial scar delineates both BFP-MSC and IL13-
MSC grafts. No noticeable differences were observed at the
level of astroglial scarring. Within the MSC graft site, a clear
side-by-side presence of grafted BFP-MSC or IL13-MSC
(Fig. 1b; arrowheads) and eGFP+ BM-derived peripheral
macrophages (Fig. 1b; arrows) can be noted. As expected,
the majority of BFP-MSC and IL13-MSC graft-invading
eGFP+ peripheral macrophages reside within the astroglial
scar (Fig. 1a). However, upon IL13-MSC grafting, the loca-
tion of eGFP+ BM-derived macrophages seems to be less re-
stricted to the implant site as compared to BFP-MSC grafts
(Fig. 1a). In this transplantation model, microglia and mac-
rophages can be distinguished following Iba1 staining
(Fig. 1c). As shown, the majority of Iba1+ cells within both
the BFP-MSC and the IL13-MSC grafts are eGFP+ macro-
phages (Fig. 1c; arrows), whereas the majority of Iba1+ cells
within the implant border are eGFP− microglia (Fig. 1c; ar-
rowheads). Further quantification indeed confirms that the
density of eGFP+ macrophages is higher within both the
BFP-MSC and the IL13-MSC graft as compared to the
graft-surrounding border (both p < 0.0001). However, more
Iba1+ eGFP+ macrophages are found in the implant border
in the case of IL13-MSC grafts as compared to BFP-MSC
grafts (p= 0.0121). For graphical representation of these re-
sults, see the description of Fig. 2c. In order to further in-
vestigate differences between BFP-MSC and IL13-MSC
graft-associated microglia and macrophages, we performed
additional immunofluorescence stainings to determine the
expression of the activation markers MHCII and arginase1
(Arg1). MHCII expression could be detected on eGFP+
macrophages and eGFP− microglia within both MSC grafts
(Fig. 1d, indicated by arrows and arrowheads, respectively).
Furthermore, while MHCII expression was rarely detected
on eGFP+ macrophages and eGFP− microglia in the border
of BFP-MSC grafts (Fig. 1d, indicated by arrows and arrow-
heads, respectively), its expression is clearly visible on both
eGFP+ macrophages and eGFP− microglia in the border of
IL13-MSC grafts (Fig. 1d, indicated by arrows and arrow-
heads, respectively). Further quantification provided in
Fig. 1e confirms that the highest density of MHCII+ cells
can be detected among eGFP+ macrophages and eGFP−
microglia within the BFP- and IL13-MSC grafts, without
significant differences between both graft types (Fig. 1e).
However, the density of MHCII+ eGFP+ macrophages and
MHCII+ eGFP− microglia in the IL13-MSC graft border is
significantly higher than in the BFP-MSC graft border
(Fig. 1e, both p = 0.0346). Next, we found that Arg1 was not
expressed on eGFP+ macrophages or eGFP− microglia
within or surrounding the BFP-MSC grafts (Fig. 1f). How-
ever, in the case of IL13-MSC grafts, it can clearly be noted
that Arg1+ eGFP+ macrophages and Arg1+ eGFP−
microglia can be detected both in and around the graft
(Fig. 1f, indicated by arrows and arrowheads, respectively).
Further quantification provided in Fig. 1g indeed confirms
that Arg1+ cells can be detected among eGFP+ macro-
phages and eGFP− microglia within and surrounding the
IL13-MSC graft (for all p = 0.0233). Another M2 activation
marker, Ym1, confirms the observation seen with Arg1
staining, showing only Ym1+ eGFP+ macrophages and
Ym1+ eGFP− microglia, in and around the IL13-MSC
graft, but not in the BFP-MSC graft (Fig. 1h, indi-
cated by arrows and arrowheads, respectively).
Detailed characterisation of IL13 induced alterations in
the occurrence and spatial distribution of microglia and
macrophage phenotypes following MSC grafting
In order to further characterise phenotypic properties of
both microglia and macrophages, we performed MHCII/
Arg1 double immunofluorescence stainings. As shown in
Fig. 2a, double staining for MHCII and Arg1 clearly shows
that in the case of IL13-MSC grafting, multiple subtypes of
both eGFP− brain-resident microglia and eGFP+ peripheral
macrophages can be visualised in and around IL13-MSC
grafts. Based on these MHCII (in blue) and Arg1 (in red)
double stainings, the following populations can be identified:
eGFP+ MHCII+ Arg1− macrophages (cyan), eGFP+ MHCII−
Arg1+ macrophages (yellow), eGFP+ MHCII+ Arg1+ macro-
phages (white), eGFP+ MHCII− Arg1− macrophages (green),
eGFP− MHCII+ Arg1− microglia (blue), eGFP− MHCII−
Arg1+ microglia (red) and eGFP− MHCII+ Arg1+ microglia
(magenta). Note that with this staining combination, eGFP−
MHCII− Arg1− microglia (black background), which are
also present, cannot be visualised in these images. When
evaluating the phenotypic properties of control BFP-MSC
graft-associated microglia and macrophages, only the fol-
lowing populations can be distinguished: eGFP+ MHCII+
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Fig. 1 (See legend on next page.)
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macrophages (cyan), eGFP+ MHCII− macrophages (green)
and eGFP− MHCII+ microglia (blue). Again, eGFP−
MHCII− microglia (black background), which are also
present, cannot be visualised on these images. Following
quantitative analysis of MHCII− and/or Arg1-expressing
cells on eGFP+ macrophages and eGFP− microglia, we cal-
culated an approximate biodistribution of the different
microglia and macrophage phenotypes observed within
and surrounding the BFP- and IL13-MSC grafts (Figs. 2b,
c). While Fig. 2b indicates each individual microglia and
macrophage subpopulations directly compared between
implant site and implant border of BFP-MSC and IL13-
MSC grafts, Fig. 2c provides overview pie charts for over-
all comparison of the differences between BFP-MSC and
IL13-MSC grafts. Note the following important similar-
ities and/or differences: (i) macrophages are the major im-
mune cell population within the BFP- and IL13-MSC
grafts; (ii) microglia are the major immune cell population
surrounding the BFP- and IL13-MSC grafts; (iii) the num-
ber of macrophages surrounding the IL13-MSC grafts is
significantly higher than the number of macrophages sur-
rounding the BFP-MSC grafts (see above; p = 0.0121); (iv)
around 50% of macrophages within the BFP-MSC grafts
express MHCII, while the majority (80 %) of macrophages
within the IL13-MSC grafts express Arg1 with half of
them co-expressing MHCII; (v) the small population of
microglia within the BFP-MSC grafts expresses MHCII,
whereas microglia within the IL13-MSC grafts display a
heterogeneous expression of MHCII and/or Arg1; (vi) in
the BFP-MSC graft border, only a small population of
microglia and macrophages express MHCII; and (vii) in
the IL13-MSC graft border, the majority of both microglia
and macrophages display a heterogeneous expression of
MHCII and/or Arg1. Overall, these results indicate that
IL13 secretion by MSC grafts induces a broad spectrum of
alternatively activated brain-resident microglia and graft-
infiltrating peripheral macrophages, both within and
around the MSC graft.
Non-invasive T2-weighted MRI reveals a protective effect
against CPZ-induced CNS inflammation and demyelin-
ation following grafting of IL13-producing MSC
Next, we investigated whether grafting of IL13-producing
MSC, and the subsequent secretion of IL13 and/or the ap-
pearance of M2 polarised microglia and macrophages,
could influence neuroinflammatory responses. For this, we
performed three independent experiments of which the de-
tails of employed mouse strains (wt C57BL/6 or C57BL/6
CX3CR1
eGFP/+ CCR2RFP/+ mice), grafted cell types (BFP-
MSC, IL13-MSC or IL13/BFP-MSC) and size of the differ-
ent experimental groups (healthy control, CPZ control,
CPZ + BFP-MSC and CPZ + IL13-MSC) are provided in
Table 1. Experimentally, 8-week-old mice received a BFP-
MSC or an IL13-MSC graft at the right side of the sple-
nium of the corpus callosum followed by a 4-week CPZ-
supplemented diet. Healthy control mice were kept on
normal rodent diet for 4 weeks, while CPZ control mice re-
ceived a 4-week CPZ-supplemented diet without undergo-
ing surgical intervention. At the age of 12 weeks, T2-
weighted MRI was applied to non-invasively measure CPZ-
induced inflammation and demyelination in the splenium
and the external capsule (EC, internal control region) [30].
As no significant differences in the calculated T2 relaxation
times for the splenium and the EC were found be-
tween wt C57BL/6 (used in experiments 1 and 2) and
C57BL/6 CX3CR1
eGFP/+ CCR2RFP/+ mice (used in ex-
periment 3), under both healthy conditions as well as
under CPZ treatment, data from all three experiments
(See figure on previous page.)
Fig. 1 Analysis of BFP-MSC and IL13-MSC graft remodelling in the CNS of eGFP+ bone marrow chimaeras. a Overview of a BFP-MSC and IL13-
MSC graft. Green: eGFP fluorescence from bone marrow-derived macrophages indicating infiltration at the graft. Red: GFAP staining indicates
astrogliosis around the graft. Scale bars indicate 200 μm. b Detail of the BFP-MSC and IL13-MSC graft. White: TOPRO-3 marking all nuclei. Green:
eGFP fluorescence from graft-infiltrating macrophages (arrows). eGFP− nuclei (arrowheads) are grafted MSC or (few) graft-infiltrating microglia.
Scale bars indicate 50 μm. Insets show BFP fluorescence (blue) or no fluorescence (black) from grafted BFP-MSC or IL13-MSC (arrowheads). Green:
eGFP fluorescence from graft-infiltrating macrophages (arrows). Scale bars indicate 20 μm. c Overview of a BFP-MSC and IL13-MSC graft. Green:
eGFP fluorescence from graft-infiltrating macrophages. Red: Iba1 staining marks both eGFP− microglia and eGFP+ macrophages. Scale bars indicate
200 μm. Details of the BFP-MSC and IL13-MSC implant and border show Iba1+eGFP+ peripheral macrophages mainly within the implant (arrows)
and Iba1+eGFP− microglia mainly within the border (arrowheads). Scale bars indicate 50 μm. d Overview of a BFP-MSC and IL13-MSC graft. Green:
eGFP fluorescence from graft-infiltrating macrophages. Red: MHCII-expressing eGFP− brain-resident microglia and eGFP+ peripheral macrophages.
Scale bars indicate 200 μm. Details of the BFP-MSC and IL13-MSC implant and border are provided, showing activated MHCII+eGFP+ macrophages
(arrows) and activated MHCII+eGFP− microglia (arrowheads). Scale bars indicate 50 μm. e Cell densities of MHCII+eGFP+ BM-derived macrophages
and MHCII+eGFP− microglia within the implant and border of BFP-MSC and IL13-MSC grafts. Values are given as mean + standard deviation. Significant
differences (p value ≤0.05) are indicated with an asterisk. f Overview of a BFP-MSC and IL13-MSC graft. Green: eGFP fluorescence from graft-infiltrating
macrophages. Red: Arg1-expressing eGFP− microglia and eGFP+ macrophages. Scale bars indicate 200 μm. Details of the BFP-MSC and IL13-MSC implant
and border are provided, showing alternatively activated Arg1+eGFP+ macrophages (arrows) and Arg1+eGFP− microglia (arrowheads). Scale bars indicate
50 μm. g Cell densities of Arg1+eGFP+ BM-derived macrophages and Arg1+eGFP− microglia within the implant and border of BFP-MSC and IL13-MSC
grafts. Values are given as mean + standard deviation. Significant differences (p value <0.05) are indicated with an asterisk. h Overview of a BFP-MSC and
IL13-MSC graft. Green: eGFP fluorescence from graft-infiltrating macrophages. Red: Ym1-expressing eGFP− microglia and eGFP+ macrophages. Scale bars
indicate 200 μm. Details of the BFP-MSC and IL13-MSC implant and border are provided, showing Ym1+eGFP+ BM-derived macrophages (arrows) and
Ym1+eGFP− microglia (arrowheads). Scale bars indicate 50 μm
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were used to increase power in further statistical analyses
(Fig. 3a, b, experiment 2 versus experiment 3, healthy con-
trol and CPZ control). When comparing the calculated T2
relaxation time for the whole splenium (both right and left
sides of the midline) and the whole EC (both right and left
sides) from healthy control mice and non-injected CPZ-
treated mice (CPZ control), it is clear that CPZ treatment
causes a significant increase of the T2 relaxation time in
both brain regions (Fig. 3a, b, for both p < 0.0001). This
can also be noted on the representative MRI images
Fig. 2 Phenotypic analysis of the different macrophage and microglia populations in BFP-MSC and IL13-MSC grafts in the CNS of eGFP+ bone
marrow chimaeras. a Overview of a BFP-MSC and IL13-MSC graft, showing MHCII-expressing (blue) and Arg1-expressing (red) microglia and macrophages.
Scale bars indicate 200 μm. Details of the BFP-MSC and IL13-MSC implant and border are provided, showing graft-infiltrating macrophages (green) in
combination with Arg1- (red) and MHCII-expressing (blue) microglia and macrophages. Scale bars indicate 50 μm. The following cell populations can be
distinguished: eGFP+MHCII+Arg1− macrophages (cyan), eGFP+MHCII−Arg1+ macrophages (yellow), eGFP+MHCII+Arg1+ macrophages (white), eGFP
+MHCII−Arg1− macrophages (green), eGFP−MHCII+Arg1− microglia (blue), eGFP−MHCII−Arg1+ microglia (red), eGFP−MHCII+Arg1+ microglia (magenta).
eGFP−MHCII−Arg1− microglia (black background) cannot be visualised using this setup. Dotted lines delineate the actual implants. The border area is an
area extending 85 μm from the implant. b Cell densities of all different cellular phenotypes characterised within the implant site (upper graph) and in
the implant border (lower graph) of BFP-MSC and IL13-MSC grafts. Values are given as mean + standard deviation. Significant differences are indicated
with one (p value <0.05), two (p value ≤0.01) or three (p value ≤0.001) asterisks. c Pie graphs showing mean representation of each microglia and
macrophage phenotype within the BFP-MSC and IL13-MSC graft and border. For the graft site, the fraction of BFP-MSC or IL13-MSC is indicated. For the
border, the fraction of other cells is indicated (*neurons, oligodendrocytes and/or astrocytes). The colours of differentially activated microglia and
macrophage correspond to those in Fig. 2a
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provided where hyperintensity regions were seen in the
splenium and EC of CPZ control mice, a finding not
observed in healthy control mice (Fig. 3a, b). When com-
paring the T2 relaxation times of the whole splenium in
BFP-MSC with IL13-MSC grafted mice, data indicate that
T2 relaxation times of IL13-MSC grafted mice, but not of
BFP-MSC grafted mice, deviate significantly less from
healthy control values compared to those obtained from
CPZ-treated mice (Fig. 3a, CPZ control versus CPZ +
IL13-MSC, p = 0.0007). This is indicative of reduced in-
flammation and demyelination in the splenium of IL13-
MSC grafted mice. The latter can also be noted on the
representative MRI images provided in Fig. 3a, where the
splenium in IL13-MSC grafted mice displays less hyperin-
tensity as compared to CPZ control mice. The observation
that T2 relaxation times of the EC remained high and were
not significantly different from those obtained in CPZ
control mice (Fig. 3b) indicates that the observed protect-
ive effect following grafting of IL13-MSC is due to the
performed cell therapeutic intervention and does not re-
sult from model failure and/or model variation. Of note,
we observed in some of the BFP-MSC grafted mice that
this procedure might have led to neuroprotection. How-
ever, as this was only observed in part of the mice from
one out of three MRI experiments, the results convince
that IL13-MSC grafting is superior to control BFP-MSC
grafting in establishing protection against inflammation
and demyelination in the whole splenium. Further analyses
over the right and left sides of the splenium by T2-weighted
MRI indicates that the protective effect of grafting IL13-
expressing MSC is of higher significant importance on the
right side of the splenium (p < 0.0001) as compared to the
left side of the splenium (p = 0.01) (Fig. 3c, d).
Histological evaluation confirms protection against CPZ-
induced CNS inflammation and demyelination by IL13-
secreting MSC
Next, we performed immunofluorescent stainings for myelin
basic protein (MBP) on C57BL/6 CX3CR1
eGFP/+ CCR2RFP/+
mice for which MRI data were obtained (MRI experiment 3,
n = 5 for healthy control, n = 5 for CPZ control, n = 5 for
CPZ + BFP-MSC and n = 7 for CPZ + IL13-MSC), and
assessed both the degree of CX3CR1
eGFP/+ microglia activity
(as determined by the percentage of eGFP coverage) and the
degree of myelination (as determined by the percentage of
MBP coverage) in the whole splenium, the right side of the
splenium and the left side of the splenium (Fig. 4). As shown
by the representative images in Fig. 4a, it is clear that the
splenium becomes highly invaded by CX3CR1
eGFP/+ micro-
glia following CPZ treatment. As expected from the above-
mentioned MRI data, representative images of IL13-MSC
grafted mice show a decrease in CX3CR1
eGFP/+ microglia
density in the splenium, which was not observed in BFP-
MSC grafted mice. In agreement with the aforementioned
MRI data, further quantitative analysis of microglia activity
(Fig. 4b) within the whole, the right and the left side of the
splenium confirms a significant decrease following grafting
of IL13-MSC over the whole splenium (p= 0.02), and more
specifically at the right side (p < 0.0001) of the splenium, as
compared to non-grafted CPZ control mice. In contrast, no
overall significant decrease in microglia activity could be de-
tected following grafting of BFP-MSC in the splenium, as
compared to non-grafted CPZ control mice. Concerning the
degree of myelination, it is clear from the representative im-
ages provided in Fig. 4a that severe demyelination can be
observed at the site of CX3CR1
+ microglia accumulation
upon CPZ administration. Moreover, as expected from the
MRI and representative images of IL13-MSC grafted mice,
protection against demyelination of the splenium is sug-
gested. Further quantitative analysis of myelination (Fig. 4c)
within the whole, the right and the left side of the splenium
confirms a significant protection against demyelination
following grafting of IL13-MSC over the whole splenium
(p = 0.0011) and the right side of the splenium (p < 0.0001),
as compared to non-grafted CPZ control mice. Again, no
overall significant protection against demyelination could
be detected following grafting of BFP-MSC in the splenium,
as compared to non-grafted CPZ control mice.
T2-weighted MRI results strongly correlate with histology
data
As we have obtained a large set of corresponding MRI
and histology data, we investigated if non-invasive T2-
weighted MRI observations can be used as a reliable
Table 1 Experimental outline of the three comparative cell grafting experiments performed in the cuprizone (CPZ) mouse model
Exp. Mouse strain Cell graft Healthy control CPZ control CPZ + BFP-MSC CPZ + IL13-MSC
1 C57BL/6 wt BFP-MSC
IL13-MSC
– – n = 5 n = 7
2 C57BL/6 wt BFP-MSC
IL13-MSC




n = 6 n = 6 n = 5 n = 7
Total number of mice n = 16 n = 16 n = 20 n = 24
Exp experiment, wt wild type, tg transgenic, MSC mesenchymal stem cell, BFP-MSC blue fluorescent protein-expressing MSC, IL13-MSC interleukin 13-expressing
MSC, IL13/BFP-MSC IL13 + BFP-expressing MSC, n number of mice
aTo avoid confusion, both IL13-producing cell lines, IL13- and IL13/BFP-MSC, will be referred to as IL13-MSC further in text
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surrogate analysis to assess inflammation and demyelination
in the CPZ mouse model. When histologically evaluating
CX3CR1
eGFP/+ microglia density and MBP myelination, a
very strong negative correlation (r = −0.789; 95 % confi-
dence interval [−0.91; −0.50]) was found between the
microglia density and myelination over the whole sple-
nium (Fig. 4d, left graph). When evaluating T2-weighted
MRI data with histological data showing CX3CR1
eGFP/+
microglia density, a strong positive correlation (r = 0.635; 95
% confidence interval [0.22; 0.86]) was found between the
increase in microglia density and the increase of T2 relax-
ation time over the whole splenium (Fig. 4d, middle graph).
When evaluating T2-weighted MRI data with histological
data showing MBP myelin density, a strong negative correl-
ation (r= -0.650; 95 % confidence interval [−0.84; −0.29])
was found between the decrease in MBP density and the in-
crease of T2 relaxation time over the whole splenium
(Fig. 4d, right graph). Based on these correlation analyses,
Fig. 3 T2-weighted MRI following injection of BFP-MSC or IL13-MSC on the right side of the splenium in CPZ-treated mice. a Left side: dot plot
showing T2-relaxation times of the whole splenium of the corpus callosum (CC) in healthy control mice (n = 16), in CPZ-treated mice (CPZ control,
n = 17), in BFP-MSC grafted CPZ-treated mice (CPZ + BFP-MSC, n = 20) and in IL13-MSC grafted CPZ-treated mice (CPZ + IL13-MSC, n = 24). Each
data point corresponds to the value obtained from an individual mouse of one of the three independent experiments (described in Table 1). The mean of
each independent experiment is represented by a horizontal line. Right side: representative MRI image demonstrating intensity alterations in the splenium
for each group (area indicated by arrows). b Left side: dot plot showing T2-relaxation times of the whole external capsule (EC) for each experimental group.
The mean of each independent experiment is represented by a horizontal line. Right side: representative MRI image demonstrating intensity alterations in
the EC for each group (area indicated by the arrows). c Dot plot showing T2-relaxation times of the right side of the splenium for each experimental group.
The mean of each independent experiment is represented by a horizontal line. d Dot plot showing T2-relaxation times of the left side of the splenium for
each experimental group. The mean of each independent experiment is represented by a horizontal line. For all dot plots, significant differences versus
the CPZ control group are indicated with one (p value <0.05), two (p value ≤0.01) or three (p value ≤ 0.001) asterisks. Data points indicated in red on
(a, b, c and d) correspond with the MRI images provided in (a and b) and the histological images shown in Fig. 4a
Le Blon et al. Journal of Neuroinflammation  (2016) 13:288 Page 11 of 20
we are confident that the observed T2-weighted MRI
images reflect the obtained histological data.
Differential behaviour of microglia and macrophages in
IL13-expressing MSC graft-mediated modulation of CPZ-
induced neuroinflammation and demyelination
Next, we took advantage of the CX3CR1
eGFP/+ CCR2RFP/+
mouse model to unravel the contribution and/or phenotypic
properties of microglia and macrophages during CPZ-
induced inflammation and the effect of IL13-expressing
MSC grafts. For this, further histological analyses were per-
formed on C57BL/6 CX3CR1
eGFP/+ CCR2RFP/+ mice from
MRI experiment 3, of which representative overview and
detail images of the splenium are provided in Fig. 5.
For each of the experimental conditions, images discrimin-
ate CX3CR1
+ microglia (eGFP fluorescence) from CCR2+
infiltrating peripheral macrophages (RFP fluorescence).
Additional activation markers, including F4/80, MHCII and
Arg1, are shown in blue (Fig. 5). While in healthy control
mice, only small numbers of CX3CR1
eGFP/+ microglia are
present within the splenium, and following CPZ treatment,
the splenium becomes highly invaded by CX3CR1
eGFP/+
microglia without noticeable contribution of CCR2RFP/+
peripheral macrophages. Representative images of IL13-
Fig. 4 Quantification of microglia and myelin coverage following injection of BFP-MSC or IL13-MSC on the right side of the splenium in CPZ-treated mice. a
Representative overview images of the splenium of the corpus callosum with CX3CR1
+ microglia (green) and MBP+ myelin (purple) in control, CPZ-treated mice
and CPZ-treated mice with BFP-MSC grafts or IL13-MSC grafts. The areas which were analysed are delineated by a dotted line. Scale bar indicates 200 μm. b
Dot plots showing the coverage percentage of eGFP in the whole splenium (left graph), the right splenium (middle graph) and the left splenium (right graph)
for each experimental group. c Dot plots showing the coverage percentage of MBP in the whole splenium (left graph), the right splenium (middle graph) and
the left splenium (right graph) for each experimental group. The mean of each independent experiment is represented by a horizontal line.
Significant differences are indicated with one (p value <0.05), two (p value≤ 0.01) or three (p value≤ 0.001) asterisks. d Dot plots showing the correlation
between eGFP and MBP coverage percentage (left graph), eGFP coverage percentage and T2 relaxation times (middle graph), MBP coverage percentage and T2
relaxation times (right graph) in the splenium for each experimental group. Spearman’s correlation coefficient (r) is presented on each graph. Data points indicated
in red on (b and c) correspond with the representative MRI images provided in Fig. 3a, b and with the representative histological images shown in (a)
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Fig. 5 Representative images illustrating multiple phenotypes of microglia and macrophages in the control and experimental groups. Representative
overview images (odd rows, scale bar indicates 200 μm) of the splenium of the corpus callosum (CC) in control mice (first column), CPZ-treated mice (second
column) and CPZ-treated mice with BFP-MSC grafts (third column) or IL13-MSC grafts (fourth column). Representative detail images (even rows, scale bar
indicates 50 μm) from the BFP-MSC or IL13-MSC graft site or from the corresponding areas in healthy control or CPZ control mice. First and second rows:
in green direct eGFP fluorescence from CX3CR1+/eGFP brain-resident microglia and in red direct RFP fluorescence from peripheral CCR2+/RFP macrophages.
Third and fourth rows: additionally in blue immunofluorescent staining for F4/80 marking activated eGFP+ brain-resident microglia and RFP+ peripheral
macrophages. Fifth and sixth rows: additionally in blue immunofluorescent staining for MHCII marking activated eGFP+ brain-resident microglia and RFP+
peripheral macrophages. Seventh and eighth rows: additionally in blue immunofluorescent staining for Arg1 marking alternatively activated eGFP+ brain-
resident microglia and RFP+ peripheral macrophages
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MSC grafted mice, but not BFP-grafted mice, show a re-
markable decrease in CX3CR1
eGFP/+ microglia density in
the whole splenium (Fig. 5, first and second rows, direct
CX3CR1-eGFP fluorescence and direct CCR-RFP fluores-
cence, quantification provided in Fig. 4b). In agreement
with our previously published data on the spatial distribu-
tion of microglia and BM-derived macrophages following
MSC transplantation in the CNS, and with the data pre-
sented in the first part of this manuscript, both MSC graft
types in CPZ-treated CX3CR1
eGFP/+ CCR2RFP/+ mice are
invaded by CCR2RFP/+ peripheral macrophages and sur-
rounded by CX3CR1
eGFP/+ brain-resident microglia (Fig. 5,
second row, direct CX3CR1-eGFP fluorescence and direct
CCR2-RFP fluorescence) [13]. Clearly, following MSC
grafting in the CPZ model, we can thus distinguish two
separate inflammatory responses: on one hand, CPZ-
induced CX3CR1
eGFP/+ microglia activation in the sple-
nium which can be modulated following grafting of IL13-
expressing MSC; on the other hand, MSC graft-associated
CX3CR1
eGFP/+ microglia and CCR2RFP/+ peripheral macro-
phage activation. Upon further evaluation of the activation
status of microglia and macrophages, by staining for
F4/80 in each of the experimental groups, it is clear
that CPZ pathology-associated CX3CR1
eGFP/+ microglia, as
well as MSC graft-associated CX3CR1
eGFP/+ microglia and
CCR2RFP/+ peripheral macrophages, express F4/80 (Fig. 5,
third and fourth rows, blue staining), while expression of
this activation marker is absent on steady-state resting
microglia in healthy brain tissue. MHCII expression is
mainly restricted to CCR2RFP/+ peripheral macrophages in-
vading the BFP-MSC graft, whereas MHCII is expressed on
both IL13-MSC graft-infiltrating CCR2RFP/+ peripheral
macrophages and on graft-surrounding CCR2RFP/+ macro-
phages and CX3CR1
eGFP/+ microglia (Fig. 5, fifth and sixth
rows, blue staining). Also note that no MHCII expression
was detected on CPZ pathology-associated CX3CR1
eGFP/+
microglia (Fig. 5, fifth and sixth rows). Finally, stain-
ing for Arg1 (Fig. 5, seventh and eighth rows, blue
staining) can only be detected on IL13-MSC graft-
infiltrating and graft-surrounding CCR2RFP/+ peripheral
macrophages and CX3CR1
eGFP/+ microglia. These results
indicate that IL13 produced by grafted MSC is able to (i)
trigger alternative activation of MSC graft-associated micro-
glia and macrophages also in the diseased brain and (ii) di-
minish CPZ-induced inflammation and demyelination by
its direct action or in combination with the action of alter-
natively activated macrophages/microglia.
Non-invasive T2-weighted MRI reveals that two injections
of IL13-expressing MSC results in superior protection
against CNS inflammation and demyelination
Given the observation that grafting of IL13-MSC on the
right side of the splenium confers histopathological pro-
tection only on the right side of the splenium, we next
investigated whether grafting of IL13-MSC on both the
left and right sides of the splenium could induce a stron-
ger and more widespread effect. In this study, 8-week-
old wild-type C57BL/6 mice were divided over three ex-
perimental groups: a healthy control group (n = 10)
which received a normal rodent diet for 4 weeks, a CPZ
control group (n = 10) which received 4 weeks of CPZ-
supplemented diet without any injections and an IL13-
MSC group (n = 10) which received 4 weeks of CPZ-
supplemented diet and IL13-MSC injections at both the
right and left sides of the splenium. First, MRI was ap-
plied to non-invasively evaluate CPZ-induced inflamma-
tion and demyelination in the splenium and the EC.
When evaluating T2 relaxation times over the whole
splenium, it is clear that grafting of IL13-MSC highly
significantly (p < 0.0001) prevents deviation from normal
T2 relaxation times upon cuprizone administration (Fig. 6a).
Again, the observed neuroprotection in the splenium is
specific to the IL13-MSC grafting procedure as T2 relax-
ation times in the EC were equally well affected by the
cuprizone diet in both the CPZ control group and the
IL13-MSC group (Fig. 6b, for both p < 0.0001). Most inter-
estingly, using this experimental setup we are able to con-
firm that grafting of IL13-MSC both on the right and left
sides of the splenium is superior to a single graft on the
right side. When evaluating T2 relaxation times separately
on the left and right sides of the splenium, it is clear that
the observed protection is now equally well distributed over
both sides of the splenium (Fig. 6c, d; for all p ≤ 0.0001).
Histological evaluation confirms that reduced
demyelination following grafting of IL13-MSC is associ-
ated with oligodendrocyte survival in the splenium of
CPZ-treated mice
In agreement with our MRI data, histological analysis first
confirmed that grafting of IL-13 MSC at both sides of the
splenium prevents demyelination over the whole splenium,
both at the right and left sides (Fig. 7a; IL13-MSC versus
CPZ control, p = 0.0045, p = 0.0025 and p = 0.0062, re-
spectively). These results thus further confirm our hypoth-
esis that grafting of IL13-MSC on both the left and right
sides of the splenium could induce a stronger and more
widespread effect as compared to IL13-MSC grafting only
at the right side (Figs. 3 and 4). Next, we aimed to investi-
gate whether the presence of myelin in the IL13-MSC
group could be related to the actual survival/presence of
oligodendrocytes. For this, an additional immunostaining
for CC1 was performed and the density of CC1+ oligoden-
drocytes was determined within the whole, left side and
right side of the splenium (Fig. 7b). While CC1+ oligo-
dendrocyte death is highly prominent in the CPZ control
group, their survival is highly significant in the whole, left
side and right side of the splenium following IL13-MSC
grafting at both the left and right sides of the splenium
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(IL13-MSC versus CPZ control, for all regions p ≤ 0.0001).
These results thus indicate that IL13-mediated modulation
of CPZ-induced inflammatory responses can interfere with
CPZ/inflammation-induced oligodendrocyte death and
subsequent demyelination. Finally, having obtained this
large dataset, Spearman correlation analysis showed a
strong positive correlation (r = 0.679; 95% confidence
interval [0.40; 0.86]) over the whole splenium between
MBP coverage percentage and CC1+ cell density (Fig. 7c,
left graph). In addition, a strong negative correlation
(r = -0.692; 95 % confidence interval [−0.87; −0.38])
was found over the whole splenium between MBP coverage
Fig. 6 T2-weighted MRI analysis following injection of IL13-MSC on the right and the left side of the splenium in CPZ-treated mice. a Left side:
dot plot showing T2-relaxation times of the whole splenium of the corpus callosum (CC) in healthy control mice (n = 10), in CPZ-treated mice (CPZ
control, n = 10) and in IL13-MSC grafted CPZ-treated mice (CPZ + IL13-MSC, n = 10). Right side: representative MRI image demonstrating intensity
alterations in the splenium for each group (area indicated by arrows). b Left side: dot plot showing T2-relaxation times of the whole external capsule (EC)
for each experimental group. Right side: representative MRI image demonstrating intensity alterations in the EC for each group (area indicated
by the arrows). c Dot plot showing T2-relaxation times of the right side of the splenium for each experimental group. d Dot plot showing T2-
relaxation times of the left side of the splenium for each experimental group. Significant differences versus the CPZ control group are indicated with
three asterisks (p value≤ 0.001). Data points indicated in red on (a, b, c and d) correspond with the MRI images provided in (a and b) and with the
histological images shown in Fig. 7a and b
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Fig. 7 (See legend on next page.)
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percentage and T2 relaxation times (Fig. 7c, middle graph).
Similarly, a strong negative correlation (r = −0.722; 95 %
confidence interval [−0.84; −0.47]) could be defined over
the whole splenium between CC1+ cell density and T2 re-
laxation times (Fig. 7c, right graph). These correlation ana-
lyses again demonstrate that the MRI analyses reflect the
obtained histological data.
Discussion
In the first part of this study, we evaluated the use of au-
tologous MSC grafts in the CNS as a delivery vehicle for
the immune modulating cytokine IL13. With regard to our
choice to use MSC as a delivery vehicle, we previously re-
ported extensively on the cellular remodelling of mesen-
chymal (stem) cell grafts in the CNS of healthy mice. From
these studies, it is now well-accepted that this intervention
is a highly complex interplay between hypoxia-induced
apoptosis of the grafted cells, neutrophil invasion, neo-
angiogenesis, microglia/macrophage recruitment, astro-
gliosis and eventually survival of a significant (5–30%)
number of grafted cells [11–15, 31]. In previous studies, we
also reported that graft-recognising microglia/macrophages
display a pro-inflammatory phenotype as shown by the
temporary expression of CD11b and MHCII. It should be
noted however that, at the time of these studies, we were
unable to experimentally distinguish brain-resident micro-
glia from CNS-invading macrophages [12]. In this new
study, we highlight the potential of IL13 secretion by
grafted MSC to induce alternative activation both in MSC
graft-surrounding microglia and in MSC graft-infiltrating
macrophages in vivo, as indicated by the expression of
Arg1 and Ym1 (Fig. 1f–h). Moreover, from our study it is
also clear that IL13 priming of macrophages and microglia
in vivo does not result in a single clearly distinguishable
cell population (Fig. 2). We may speculate that each of the
microglia or macrophage phenotypes described, either sin-
gle positive for MHCII, single positive for Arg1 or double
positive, may exert a different effector function; however,
this remains to be further investigated on the single cell
level. Thus far, apart from the induction of markers associ-
ated with alternative activation, we currently do not know
what influence IL13 and/or M2 polarised microglia/macro-
phages display on the in vivo survival of autologous MSC
grafts and/or their in vivo remodelling. While our first ob-
servations do not indicate a major difference between au-
tologous MSC grafts with and without genetic engineering
to secrete IL13 (Fig. 1a–e), we recently reported that trans-
plantation of allogeneic MSC genetically engineered to se-
crete IL13, with subsequent induction of Arg1, Ym1 and
Fizz1 expression in MSC graft-recognising microglia and/
or macrophages, leads to highly reduced downstream ef-
fector function in terms of (i) direct in vivo recognition
and elimination of allogeneic cellular grafts and (ii) in vivo
induction of allogeneic T cell immune responses [32]. Al-
though the process of direct and indirect allorecognition
does not occur with autologous (syngeneic) cellular grafts,
we may speculate that IL13 can have a beneficial effect on
long-term engraftment of autologous MSC grafts in the
CNS; however, this needs further investigation.
In the second part of our manuscript, we provide a thor-
ough analysis of MSC graft-mediated IL13 delivery as an
effective approach to modulate pathology-associated im-
mune responses in the CNS of mice. We here highlight
that IL13 production by grafted MSC, potentially aided by
the appearance of alternatively activated microglia and
macrophages at the MSC graft site, prevents microgliosis,
oligodendrocyte death and demyelination in the CPZ
mouse model (Figs. 4 and 7). Note that the therapeutic
approach presented here, i.e. intracerebral grafting of
IL13-producing MSC, is significantly different from sev-
eral previously published reports regarding the therapeutic
use of non-engineered MSC in the CPZ mouse model. A
study by Nessler and colleagues was unable to report any
clinical benefit of both intravenously or intranasally ad-
ministered MSC [33], most likely due to limited cell mi-
gration to the CNS. In addition, our own preceding work
on cell grafting in the CPZ model at the peak of inflamma-
tion and demyelination was also unable to demonstrate
(See figure on previous page.)
Fig. 7 Quantification of myelin coverage and oligodendrocyte density following injection of IL13-MSC on the right and left sides of the splenium
in CPZ-treated mice. a Upper row: representative overview images of the splenium of the corpus callosum stained for MBP (red) in control, CPZ-
treated mice and CPZ-treated mice with IL13-MSC grafts. The areas which were analysed are delineated by a dotted line. Scale bar indicates 200 μm.
Lower row: dot plots showing the coverage percentage of MBP over the whole splenium (left graph), the left side of the splenium (middle graph) and the
right side of the splenium (right graph) for each experimental group. The mean of each group is represented by a horizontal line. Significant differences
are indicated with two (p value ≤0.01) or three (p value ≤0.001) asterisks. b Upper row: representative overview images of the splenium of the corpus
callosum stained for CC1+ oligodendrocytes (red) in control, CPZ-treated mice and CPZ-treated mice with IL13-MSC grafts. The areas which
were analysed are delineated by a dotted line. Scale bar indicates 100 μm. Lower row: dot plots showing the cell density (cells/mm2) of CC1+
oligodendrocytes over the whole splenium (left graph), the left side of the splenium (middle graph) and the right side of the splenium (right
graph) for each experimental group. The mean of each group is represented by a horizontal line. Significant differences are indicated with two
(p value ≤0.01) or three (p value ≤0.001) asterisks. c Dot plots showing the correlation between MBP coverage percentage and CC1+ oligodendrocyte cell
density (left graph), MBP coverage percentage and T2 relaxation times (middle graph), CC1
+ oligodendrocyte cell density and T2 relaxation times (right
graph) in the whole splenium for each experimental group. Spearman’s correlation coefficient (r) is presented on each graph. Data points indicated in red
on (a and b) correspond with the representative MRI images provided in Fig. 6a, b and with the representative histological images shown in (a and b)
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any contribution of mesenchymal, neural or haematopoi-
etic cells to remyelination [14]. The latter observation was
recently confirmed by a study performed by Salinas Teje-
dor et al. showing that MSC injected at the onset or the
peak of oligodendrocyte proliferation during cuprizone-
induced demyelination do not exert beneficial effects on
remyelination [34]. Although all these studies question the
use of MSC to exert direct neuroprotective effects in the
CPZ model, we here provide an alternative approach in
which we demonstrate that autologous MSC are well-
suited as transplantable carrier cells for the direct delivery
of a therapeutic protein to the injured CNS, as proven in
the current study for the M2-polarising cytokine IL13.
However, currently still open for debate is the actual work-
ing mechanism for the observed neuroprotective character
of MSC-mediated IL13 delivery in the CNS. Based on our
current knowledge, and in agreement with several litera-
ture reports, we propose the following working hypothesis.
Previously, it has been described by Yang et al. that IL13
can directly induce apoptosis in activated microglia [35]. It
is not unlikely that this feature of IL13 highly contributes
to the reduced microgliosis, and subsequent reduced
oligodendrocyte death and demyelination, observed in this
study. Although we prefer to support this first hypothesis,
M2 polarised macrophages/microglia, which are effectively
introduced in the CNS by means of local transplantation
of IL13-producing MSC, may also indirectly contribute to
the observed protection against demyelination. In this con-
text, it has previously been reported that M2 polarised
macrophages are able to promote oligodendrocyte differ-
entiation and enhance remyelination [36]. However, using
the current experimental setup we cannot make a clear
distinction between protection against inflammation-
induced oligodendrocyte death and/or already occurred
oligodendrocyte regeneration. Likewise, given the intrinsic
toxic nature of CPZ to oligodendrocyte metabolism [17],
it remains to be elucidated whether the observed myelin is
fully functional on the structural and functional level. For
this, electron microscopy [37, 38] and more advanced
MRI studies [26, 27, 39] are planned in our future experi-
ments. Nevertheless, as the field of CNS immunomodula-
tion is highly complex and continuously evolving, a highly
complex interplay between both proposed mechanisms
may not be not unlikely.
Finally, we would like to elaborate a little on the pro-
posed experimental strategies used in this study. First, we
applied non-invasive T2-weighted MRI (Figs. 3 and 6) and
correlated these findings with post-mortem histological
analyses (Figs. 4 and 7). Although MRI analyses are not
novel for the CPZ mouse model, we here demonstrate that
therapeutic interventions in the CPZ mouse model can
successfully be detected by means of T2-weighted MRI.
Therefore, longitudinal MRI studies of the CC in the CPZ
mouse model may/should become highly complementary
to single point post-mortem histological analyses when ap-
plying therapeutic interventions, as previously suggested by
us [39]. Second, our MSC implantation approach deserves
some special attention. The presented studies here suggest
that multiple injections of IL13-MSC are superior over a
single injection (Figs. 3, 4, and 5 versus Figs. 6 and 7). Al-
though this approach solves the issue of the limited local
action of IL13-MSC grafting, one should take caution with
multiple cellular injections in the CNS, especially when
considering human applications in future. However, as to
date the exact working mechanism of cellular therapies in
the CNS is largely unresolved, in addition to the direct ac-
tion of IL13, we previously already suggested that MSC
graft-induced inflammatory responses (in this study the
introduction of M2 polarised macrophages into the CNS)
may lie at the basis of observed neuroprotective and/or re-
generative responses [31].
Conclusions
With this study, we propose a novel approach for effect-
ive modulation of detrimental in vivo inflammatory re-
sponses in the CNS, where IL13 production by grafted
MSC and potentially aided by the appearance of alterna-
tively activated microglia and macrophages at the MSC
graft site, induces microglial quiescence and subsequent
protection against oligodendrocyte death and demyelin-
ation in the CPZ mouse model for CNS inflammation
and demyelination. In this context, we believe our ex-
perimental approach to be worthy of further evaluation
in clinically relevant mouse models of neurotrauma dis-
playing a gradual increase in inflammatory responses,
e.g. models of spinal cord injury or stroke.
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